Search

Your search keyword '"Johansson Alm, Sofie"' showing total 6 results
Start Over Author "Johansson Alm, Sofie"
6 results on '"Johansson Alm, Sofie"'

2. Comparison of RNA‐ and DNA‐based methods for measurable residual disease analysis in NPM1 ‐mutated acute myeloid leukemia

Author

Pettersson, Louise, primary, Johansson Alm, Sofie, additional, Almstedt, Alvar, additional, Chen, Yilun, additional, Orrsjö, Gustav, additional, Shah‐Barkhordar, Giti, additional, Zhou, Li, additional, Kotarsky, Heike, additional, Vidovic, Karina, additional, Asp, Julia, additional, Lazarevic, Vladimir, additional, Saal, Lao H., additional, Fogelstrand, Linda, additional, and Ehinger, Mats, additional

Published
2021
Full Text
View/download PDF

4. Measurable Residual Disease Assessment By qPCR in Peripheral Blood Is an Informative Tool for Disease Surveillance in Childhood Acute Myeloid Leukemia

Author

Juul-Dam, Kristian, primary, Ommen, Hans Beier, additional, Nyvold, Charlotte Guldborg, additional, Walter, Christiane, additional, Vålerhaugen, Helen, additional, Kairisto, Veli, additional, Abrahamsson, Jonas, additional, Johansson Alm, Sofie, additional, Jahnukainen, Kirsi, additional, Lausen, Birgitte, additional, Reinhardt, Dirk, additional, Zeller, Bernward, additional, Von Neuhoff, Nils, additional, Fogelstrand, Linda, additional, and Hasle, Henrik, additional

Published
2018
Full Text
View/download PDF

5. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML

Author

Delsing Malmberg, Erik, primary, Johansson Alm, Sofie, additional, Nicklasson, Malin, additional, Lazarevic, Vladimir, additional, Ståhlman, Sara, additional, Samuelsson, Tore, additional, Lenhoff, Stig, additional, Asp, Julia, additional, Ehinger, Mats, additional, Palmqvist, Lars, additional, Brune, Mats, additional, and Fogelstrand, Linda, additional

Published
2018
Full Text
View/download PDF

6. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.

Author

Delsing Malmberg, Erik, Johansson Alm, Sofie, Asp, Julia, Palmqvist, Lars, Fogelstrand, Linda, Nicklasson, Malin, Brune, Mats, Lazarevic, Vladimir, Lenhoff, Stig, Ståhlman, Sara, Samuelsson, Tore, and Ehinger, Mats

Subjects
*STEM cell transplantation, *HEMATOPOIETIC stem cell transplantation, *ACUTE myeloid leukemia, *GENE frequency
Abstract

Mutations in NPM1 can be used for minimal residual disease (MRD) analysis in acute myeloid leukemia (AML). We here applied a newly introduced method, deep sequencing, allowing for simultaneous analysis of all recurrent NPM1 insertions and thus constituting an attractive alternative to multiple PCRs for the clinical laboratory. We retrospectively used deep sequencing for measurement of MRD pre- and post-allogeneic hematopoietic stem cell transplantation (alloHCT). For 29 patients in morphological remission at the time of alloHCT, the effect of deep sequencing MRD on outcome was assessed. MRD positivity was defined as variant allele frequency ≥0.02%. Post-transplant MRD status was significantly and independently associated with clinical outcome; 3-year relapse-free survival 20% vs 85% (p < .001), HR 45 (95% CI 2-1260), and overall survival 20% vs 89% (p < .001), HR 49 (95% CI 2-1253). Thus, the new methodology deep sequencing is an applicable and predictive tool for MRD assessment in AML. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results